What Factor Bioscience does

Factor Bioscience Inc. is a privately held, pre-clinical biotechnology company headquartered in Cambridge, Massachusetts, founded in 2011 with 1-10 employees. The company develops gene-edited cell therapies built on an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies developed over approximately 15 years. Its active programs include FACT-112, an IL12-expressing iMacrophage candidate designed to repolarize immunosuppressive tumor microenvironments in solid tumors such as ovarian cancer; iPSC-derived mesenchymal stem cells targeting muscular dystrophy and neurodegenerative disorders; and gene-edited hypoimmune iPSC cell lines designed to reduce immunogenicity across cell therapy indications.

The company's scientific activities are evidenced by seven presentations at the ASGCT 29th Annual Meeting (Boston, May 2026) and pre-clinical data at ISCT 2026 (Dublin). In February 2026, Factor divested four dual-targeting CAR-T programs, including the clinical-stage CD19/BCMA candidate TPST-2003, to Tempest Therapeutics in an all-stock transaction, with co-founder Dr. Matt Angel departing to become President and CEO of Tempest. Factor retains operational independence and continues to advance the remaining platform programs.

Factor Bioscience operates as a technology licensor and platform provider rather than a direct commercial developer. Revenue mechanics consist of non-dilutive grant funding (including a U.S. Department of Defense grant awarded in January 2024 for Duchenne muscular dystrophy research) and partnership milestone/option payments (including a success payment from Lineage Cell Therapeutics in January 2026 tied to a hypoimmune iPSC cell line delivery). Pricing is not publicly disclosed and the company is pre-revenue, with no disclosed institutional venture financing. Customers and partners to date include the U.S. Department of Defense, Lineage Cell Therapeutics, and Tempest Therapeutics.

Name

Factor Bioscience

Legal name

Factor Bioscience Inc.

Website

https://factorbio.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Factor Bioscience is a pre-clinical Cambridge, Massachusetts biotechnology company developing gene-edited cell therapies on a patented mRNA, cell-reprogramming, and gene-editing platform, targeting solid tumors, muscular dystrophy, and neurodegenerative disorders via licensing and partnerships.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

Keywords

• Gene-editing technology
• MRNA cell engineering
• IPSC cell therapy
• Regenerative medicine
• Cell reprogramming

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Distribution channels1 record

Marketing channels1 record

Core offering

Factor Bioscience develops an integrated platform of patented mRNA, cell-reprogramming, and gene-editing technologies for creating scalable, off-the-shelf gene-edited cell therapies. Its pipeline includes IL12-expressing iMacrophages (FACT-112) for solid tumors, iPSC-derived mesenchymal stem cells for muscular dystrophy and neurodegenerative disorders, dual-targeting CAR-T programs, and hypoimmune iPSC cell lines licensed to partners.

Product overview

Factor Bioscience is a Cambridge, Massachusetts-based biotechnology company that has developed a proprietary platform of patented mRNA, cell-reprogramming, and gene-editing technologies. The company operates multiple engineered cell therapy programs including: FACT-112 (IL12-expressing iMacrophages for solid tumors), iPSC-derived Mesenchymal Stem Cells for muscular dystrophy and neurodegenerative disorders, and Next-Generation CAR-T Approaches featuring dual-targeting technologies. The platform is built on 15 years of development in RNA-enabled cell engineering, with off-the-shelf cell therapy capabilities. The company also developed hypoimmune iPSC cell lines through partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• FACT-112 (IL12-expressing iMacrophages)
• iPSC-derived Mesenchymal Stem Cells
• Next-Generation Dual-Targeting CAR-T Programs
• RNA-Enabled Cell Engineering Platform
• Gene-Edited Hypoimmune iPSC Cell Line

Quantifiable outcome

• 100% complete response rate observed in CAR-T-naïve patients treated with TPST-2003 across REDEEM-1 and POEMS-1 trials (data generated by acquirer Tempest Therapeutics)
• +1 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Lineage Cell TherapeuticscoreStrategic or Co-development Partner · 6 January 2026Strategic collaboration where Lineage Cell Therapeutics received a novel gene-edited hypoimmune iPSC cell line from Factor Bioscience. Acceptance of the cell line triggered a success payment from Lineage to Factor. Lineage retains an option to obtain an exclusive license for preclinical, clinical, and commercial use of the cell line. The cell line contains specific edits designed to reduce immunogenicity and prevent adverse immune responses across a range of cell therapy indications.
• Tempest TherapeuticscoreStrategic or Co-development Partner · 19 November 2025All-stock acquisition of four dual-targeting CAR-T programs from Factor Bioscience and Erigen LLC by Tempest Therapeutics. Following the transaction, Factor's co-founder Dr. Matt Angel became President and CEO of Tempest. The acquisition included clinical-stage CD19/BCMA CAR-T candidate (TPST-2003) with a planned BLA filing in China for 2027. An investment commitment from Factor extended Tempest's operational runway to mid-2027. Existing Tempest shareholders retained approximately 35% of the pro forma company.
• Erigen LLCminorStrategic or Co-development Partner · 19 November 2025Jointly with Factor Bioscience, Erigen LLC sold dual-targeting CAR-T programs to Tempest Therapeutics in an all-stock transaction. The combined asset sale with Factor formed the basis of Tempest's strategic pivot and CAR-T expansion strategy.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Vertex Pharmaceuticals: Vertex Pharmaceuticals has built a significant cell therapy and regenerative medicine franchise including DMD programs following its acquisition of Alpine Immune Sciences. It competes with Factor's DMD gene-edited cell therapy efforts as a much larger and better-capitalized player.
• Editas Medicine: Editas Medicine is a clinical-stage gene-editing company developing CRISPR-based therapeutics including ex vivo cell therapies. It is a broader incumbent in the gene-editing space that Factor competes with for talent, capital, and partnerships.
• Beam Therapeutics: Beam Therapeutics is a clinical-stage base-editing company with cell therapy and in vivo programs. It is a broader incumbent in precision gene editing relevant to Factor's platform technology stack.

Direct peers

• Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies including engineered NK and T-cell candidates with gene-editing modifications. It is one of the closest direct peers to Factor's allogeneic, gene-edited iPSC platform approach.
• Caribou Biosciences: Caribou Biosciences is a clinical-stage CRISPR genome-editing company developing allogeneic CAR-T cell therapies. It is a direct peer in the intersection of gene editing and cell therapy that defines Factor Bioscience's core platform.
• Fate Therapeutics: Fate Therapeutics is a clinical-stage iPSC-derived cell therapy company developing off-the-shelf NK and T-cell candidates for cancer and autoimmune disease. It directly parallels Factor Bioscience's iPSC platform approach to allogeneic cell therapy and competes for the same licensing and partnership ecosystem.
• Lineage Cell Therapeutics: Lineage Cell Therapeutics is an allogeneic cell therapy developer and is Factor's active collaboration partner, holding an option to license Factor's hypoimmune iPSC cell line. It is a direct peer in cell therapy development and a meaningful commercial counterpart for Factor's platform.
• Sana Biotechnology: Sana Biotechnology develops hypoimmune-modified cell therapies and in vivo gene editing/cell engineering approaches. It shares Factor's focus on reducing immunogenicity to enable off-the-shelf cell therapies and pursues a similar platform-plus-pipeline model.
• Lyell Immunopharma: Lyell Immunopharma develops next-generation cell therapies for solid tumors, with programs focused on T-cell exhaustion resistance and tumor microenvironment modulation. It overlaps with Factor's solid tumor programs such as FACT-112 iMacrophages.

Emerging players

• Carisma Therapeutics: Carisma Therapeutics is developing engineered macrophage cell therapies (CAR-M) for solid tumors. Its macrophage-focused approach directly parallels Factor's FACT-112 IL12-expressing iMacrophage program and represents an emerging competitor in macrophage-based oncology cell therapy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/factorbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Factor Bioscience